poly-cystic ovarian syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Diagnosis of Polycystic Ovarian Syndrome Based on Rotterdam Criteria By clinical practitioner
Exclusion criteria
Exclusion criteria: Family history of breast, ovarian or uterine cancer Alcohol or drug use Pregnancy or lactation Use of anti-hypertension and lipid lowering drugs Metformin use 6 months before enrollment and during the study Diabetes, thyroid disease or any systemic disease (eg kidney, liver, digestive system, cardiovascular) Other disorders that lead to increased androgens in the blood (such as Cushing's syndrome, hyper prolactinemia) Menopause Use of drugs that affect glucose metabolism
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ?Fasting Blood Sugar. Timepoint: At the beginning and the end of the study (after 8 weeks ). Method of measurement: FBS kit.;Insulin. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Insulin kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Luteinizing Hormone. Timepoint: At the beginning and the end of the study (after 8 weeks ). Method of measurement: Luteinizing Hormone kit.;Follicle-Stimulating Hormone. Timepoint: At the beginning and the end of the study (after 8 weeks ). Method of measurement: Follicle-Stimulating Hormone kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Shiraz University of Medical Sciences